SDGR
Schrodinger Inc
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
News
- Schrödinger announces discontinuation of SGR-2921 programAug 14, 2025
- Schrödinger receives Fast Track designation for SGR-1505 to treat relapsed/refractory Waldenström macroglobulinemiaJun 29, 2025
- Schrödinger shares promising Phase 1 results for SGR-1505 at EHA Annual CongressJun 12, 2025
- Schrödinger to present Phase 1 clinical data on MALT1 inhibitor SGR-1505 at the EHA Annual Congress and International Conference on Malignant Lymphoma.May 14, 2025